Repurposed Drugs and Covid-19 Pandemic-What and Why? | Zendy

Jeevan Ranjan Dash | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Repurposed Drugs and Covid-19 Pandemic-What and Why?

Author(s) -

Jeevan Ranjan Dash

Publication year - 2021

Publication title -

the journal of phytopharmacology

Language(s) - English

Resource type - Journals

ISSN - 2320-480X

DOI - 10.31254/phyto.2021.10507

Subject(s) - covid-19 , pandemic , repurposing , drug repositioning , clinical trial , medicine , drug , intensive care medicine , risk analysis (engineering) , disease , pharmacology , infectious disease (medical specialty) , virology , engineering , outbreak , pathology , waste management

New remedies for COVID-19 are the demand of time as we live in a phase beyond containment in this current pandemic. Its impractical to think of a quick relief immediately as drug development from a scratch is not an easy and quick process. Repurposing of drugs might be a method where drugs already tested safe to humans will be redeployed to curb a disease. Use of repurposed drugs alone may not be able to produce a clear and advantageous clinical result where a carefully combined cocktails could be a good alternative, as seen in treatment of HIV in the 1990s. But the most important question now is now, which combination? This article gives a detailed review on repurposed drugs under clinical trial for COVID-19 to find out a suitable cocktail

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research